Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilfried Ernst Erich Eberhardt

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 23, 2013
Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancerThomas Christoph Gauler, Daniel Christian Christoph, Juergen Fischer, et al.
Journal of Thoracic Disease|April 30, 2015
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyChristoph Pöttgen, Jehad Abu Jawad, Eleni Gkika, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2015
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational studyWolfgang Schuette, Peter Schirmacher, Wilfried Ernst Erich Eberhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2013
Strategies for improving outcomes in NSCLC: a look to the futureRolf Stahel, Solange Peters, Paul Baas, et al.
Cancer Management and Research|October 3, 2019
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesotheliomaRobert Fred Henry Walter, Saskia Roxanne Sydow, Erika Berg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2021
Impact of EBUS-TBNA in addition to [<sup>18</sup>F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLCMaja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2013
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|May 23, 2013
Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancerThomas Christoph Gauler, Daniel Christian Christoph, Juergen Fischer, et al.
Journal of Thoracic Disease|April 30, 2015
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyChristoph Pöttgen, Jehad Abu Jawad, Eleni Gkika, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2015
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational studyWolfgang Schuette, Peter Schirmacher, Wilfried Ernst Erich Eberhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2013
Strategies for improving outcomes in NSCLC: a look to the futureRolf Stahel, Solange Peters, Paul Baas, et al.
Cancer Management and Research|October 3, 2019
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesotheliomaRobert Fred Henry Walter, Saskia Roxanne Sydow, Erika Berg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2021
Impact of EBUS-TBNA in addition to [<sup>18</sup>F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLCMaja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2013
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Pageof 2